+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients



LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients



Evidence-BasedMedicine21(6):222




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058191152

Download citation: RISBibTeXText

PMID: 27634637

DOI: 10.1136/ebmed-2016-110525


Related references

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 12: 907-922, 2017

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. International Journal of Chronic Obstructive Pulmonary Disease 13: 3115-3130, 2018

An update on LAMA/LABA combinations for COPD. Drug and Therapeutics Bulletin 55(1): 2-5, 2017

Use of ICS/LABA Combinations or LAMA Is Associated with a Lower Risk of Acute Exacerbation in Patients with Coexistent COPD and Asthma. Journal of Allergy and Clinical Immunology. in Practice 6(6): 1927-1935.E3, 2018

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD. Clinicoeconomics and Outcomes Research 8: 667-674, 2016

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. International Journal of Chronic Obstructive Pulmonary Disease 14: 531-546, 2019

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 13: 3203-3231, 2018

Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD. Expert Review of Respiratory Medicine 10(7): 767-780, 2016

A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD. Expert Opinion on PharmacoTherapy 18(17): 1833-1843, 2017

LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. International Journal of Chronic Obstructive Pulmonary Disease 10: 1093-1102, 2015

A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opinion on Drug Safety 17(5): 509-517, 2018

Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice. Chest 155(6): 1158-1165, 2019

Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2: Cd012066, 2017

P59Factors influencing step-up to lama+laba/ics in Copd patients initially on lama monotherapy: a thin database study. Thorax 71(Suppl 3): A116.1-A116, 2016

LAMA/LABA supports physical activity in COPD patients. MMW Fortschritte der Medizin 158(2): 71, 2016